RAS testing of colorectal carcinoma - A guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Journal of Clinical Pathology

Volumn 67, Issue 9, 2014, Pages 751-757

  Wong, Newton A C S ^a   Gonzalez, David ^b   Salto Tellez, Manuel ^c   Butler, Rachel ^d   Diaz Cano, Salvador J ^e   Ilyas, Mohammad ^f   Newman, William ^g   Shaw, Emily ^h   Taniere, Philippe ⁱ   Walsh, Shaun V ^j  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f QUEEN S MEDICAL CENTRE   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j NINEWELLS HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA; PANITUMUMAB; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ARTICLE; CANCER TISSUE; CODON; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DNA DEGRADATION; DNA TEMPLATE; ENDOSCOPIC BIOPSY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LABORATORY TEST; MEDICAL AUDIT; MEDICAL SOCIETY; METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; PATHOLOGIST; PATIENT SELECTION; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYROSEQUENCING; QUALITY CONTROL; SOMATIC MUTATION; TUMOR BIOPSY; TUMOR CELL; TURNAROUND TIME; VALIDATION PROCESS; WILD TYPE; CARCINOMA; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HEALTH CARE QUALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; STANDARDS;

CARCINOMA; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GTP PHOSPHOHYDROLASES; HUMANS; INDIVIDUALIZED MEDICINE; MEMBRANE PROTEINS; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; QUALITY CONTROL; QUALITY OF HEALTH CARE; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84921946952     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202467     Document Type: Article

References (40)

1. CancerResearchUK. [cited 2014 12 May]. http://www.cancerresearchuk.org/ cancer-info/cancerstats/types/bowel/
2. ACPGBI, RCSEng, HSCIC. National Bowel Cancer Audit Annual Report 2013 [cited 2014 12 May]. 29-38 http://www.acpgbi.org.uk/members/groups/nbocap/
3. Kjeldsen BJ, Kronborg O, Fenger C, et al. The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. Int J Colorectal Dis 1997;12:329-34. (Pubitemid 28017718)
4. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535-46.
5. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
6. NICE. Cetuximab for the first-line treatment of metastatic colorectal cancer 2009 [cited 2014 12 May]. http://publications.nice.org.uk/cetuximab-for- the-first-line-treatment-of-metastatic-colorectal-cancer-ta176
7. NICE. TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): guidance 2012 [cited 2014 21 May]. http://guidance.nice.org.uk/TA242/Guidance/pdf/English
8. Garcia-Alfonso P, Salazar R, Garcia-Foncillas J, et al. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol 2012;14:726-39.
9. Kamel-Reid S, Zhang T, Persons DL, et al. Molecular Oncology Resource Committee of the College of American P. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med 2012;136:26-32.
10. Normanno N, Pinto C, Castiglione F, et al. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PloS One 2011;6:e29146.
11. Han CB, Li F, Ma JT, et al. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012;30:741-7.
12. Kim MJ, Lee HS, Kim JH, et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC cancer 2012;12:347.
13. Pang NK, Nga ME, Chin SY, et al. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology 2011;22:358-64.
14. Ilyas M, Straub J, Tomlinson IP, et al. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999;35:1986-2002. (Pubitemid 30026220)
15. Fadhil W, Ibrahem S, Seth R, et al. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. Histopathology 2012;61:1117-24.
16. Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol 2011;34:61-6.
17. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9.
18. Goranova TE, Ohue M, Shimoharu Y, et al. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis 2011;28:427-35.
19. Bando H, Yoshino T, Tsuchihara K, et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 2011;105:403-6.
20. Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011;17:4901-14.
21. Dono M, Massucco C, Chiara S, et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol Med 2012;18:1519-26.
22. Santini D, Galluzzo S, Gaeta L, et al. Should oncologists be aware in their clinical practice of KRAS molecular analysis? J Clin Oncol 2011;29:e206-7; author reply e8-9.
23. Diaz LA Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
24. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
25. Groenen PJ, Blokx WA, Diepenbroek C, et al. Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology 2011;59:1-7.
26. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002;161:1961-71. (Pubitemid 35434840)
27. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999;155:1467-71.
28. Baloglu G, Haholu A, Kucukodaci Z, et al. The effects of tissue fixation alternatives on DNA content: a study on normal colon tissue. Appl Immunohistochem Mol Morphol 2008;16:485-92.
29. Deans ZC, Tull J, Beighton G, et al. Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer. Genet Test Mole Biomarkers 2011;15:777-83.
30. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-52.
31. Gonzalez de Castro D, Angulo B, Gomez B, et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer 2012;107:345-51.
32. Harle A, Busser B, Rouyer M, et al. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. Virchows Arch 2013;462:329-35.
33. Malapelle U, Carlomagno C, de Luca C, et al. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. J Clin Pathol 2014;67:1-9.
34. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
35. Schwartzberg LS, Rivera F, Karthaus M, et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) 2013 [cited 2014 25 March]. abstract 3631]. http://meetinglibrary.asco.org/content/116726-132
36. Stintzing S, Jung A, Rossius L, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3. A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. 2013 [cited 2014 25 March]. http://web.oncoletter. ch/files/cto-layout/Kongressdateien/ECCO%20ESMO%202013/ECC%202013-FIRE- 3%20final-20130928.pdf
37. Mattocks CJ, Morris MA, Matthijs G, et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010;18:1276-88.
38. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 2012;30:3565-7.
39. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
40. Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430-5.